HTA and Beijing Normal University signed a cooperation framework agreement in Beijing. Beijing Normal University School of Chemistry Party Secretary Yang Zhao, Vice President Yang Qingzheng; Atomic High-tech general manager Zhao Jing, deputy Party secretary, deputy general manager Li Guoxiang, deputy general manager Sui Yanying attended the ceremony.
Zhao Jing and Li Guoxiang signed the cooperation framework agreement and the scholarship fund agreement with Yang Zhao respectively. According to the agreement, the two sides will give full play to the advantages of both schools and enterprises in personnel training, scientific and technological innovation, discipline construction, platform construction and other aspects, establish a comprehensive cooperative relationship on the basis of mutual benefit and common development, and achieve collaborative innovation and high-quality development of schools and enterprises.
Subsequently, experts and professors of Beijing Normal University and scientific researchers of atomic science and technology exchanged on the progress of drug release technology. Cui Mengchao, professor of Beijing Normal University, introduced the basic research and clinical transformation of molecular probes for central nervous system and tumor, Zhang Junbo introduced the research of novel PSMA-targeting 99mTc labeled glutamate-urea derivative tumor molecular probes, and Cao Wei introduced polymer nanoassemblies for the combination of radiotherapy and chemotherapy. Wen Kai, deputy manager of the R&D department of HTA, introduced the development and scientific research progress of atomic High Technology.
Yang Qingzheng expressed sincere thanks to HTA for the work done for the cooperation and exchange between the two sides, and said that Beijing Normal University has a long history and distinctive characteristics, and the School of Chemistry has been deeply engaged in the development of radiopharmaceutical research and development industry for decades. At the same time, as the key laboratory of Radiopharmaceuticals of the Ministry of Education, we have accumulated rich experience in radiopharmaceuticals and trained many talents. It is hoped that the two sides can strengthen collaborative innovation in the future, promote complementary advantages, take the deep cooperation between schools and enterprises as an opportunity, deeply grasp the development trend of drug release, and support high-level science and technology self-reliance.
Yang Zhao pointed out that HTA, as a leading state-owned enterprise in the field of nuclear medicine in China, has been working closely with the school. She expects that through this cooperation, resources will be shared, advantages will be complementary, key technology research will be carried out, talent training will be improved to meet the needs of the industry, and technological innovation in the industry will be seized.
Li Guoxiang said that the signing of the school-enterprise cooperation strategic agreement is an effective way to promote the co-construction and sharing of school-enterprise advantageous resources and achieve win-win development. He hoped that Beijing Normal University and HTA will take the signing of the strategic cooperation agreement as a new starting point to carry out broader, deeper and more cooperation and exchanges, jointly tackle a number of high-quality development of drug industry enterprises in the key technology, build a number of high-level drug technology innovation platforms, transform a number of high-quality scientific and technological innovation achievements.
Zhao Jing affirmed a series of cooperation achievements made by the two sides in scientific and technological innovation and personnel training. The two sides have successfully transformed industry-university-research cooperation projects and jointly applied for National Natural Science Fund projects. The signing of this strategic cooperation agreement marks a new level of cooperation between the two sides. Facing the future, he hopes that the two sides will carry out more extensive and deeper cooperation, jointly transform the innovation and talent advantages of the two sides into high-quality development advantages, promote the innovation chain, industrial chain, education chain and talent chain, and make positive contributions to the independence and self-improvement of high-level science and technology in radiopharmacology research and development.
